Sartorius Stedim Biotech (Sartorius Stedim Biotech) ROCE % : 5.65% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Sartorius Stedim Biotech ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sartorius Stedim Biotech's annualized ROCE % for the quarter that ended in Dec. 2023 was 5.65%.

Sartorius Stedim Biotech ROCE % Historical Data

The historical data trend for Sartorius Stedim Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius Stedim Biotech ROCE % Chart

Sartorius Stedim Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

24.44

26.10

24.44

32.19

9.67

Sartorius Stedim Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															22.41	17.04	18.20	5.38	5.65

Sartorius Stedim Biotech ROCE % Calculation

Sartorius Stedim Biotech's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	564.995	/	( ( (5365.89 - 1097.352)	+	(8440.458 - 1022.137) )	/ 2 )
	=	564.995	/	( (4268.538	+	7418.321)	/ 2 )
	=	564.995	/	5843.4295
	=	9.67 %

Sartorius Stedim Biotech's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	423.992	/	( ( (8494.023 - 910.993)	+	(8440.458 - 1022.137) )	/ 2 )
	=	423.992	/	( ( 7583.03	+	7418.321 )	/ 2 )
	=	423.992	/	7500.6755
	=	5.65 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Sartorius Stedim Biotech (OTCPK:SDMHF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sartorius Stedim Biotech ROCE % Related Terms

Thank you for viewing the detailed overview of Sartorius Stedim Biotech's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sartorius Stedim Biotech (Sartorius Stedim Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius Stedim Biotech SA (OTCPK:SDMHF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

SRTOY:USA DIM:Mexico DIMp:UK 0RG8:UK DIM:France 56S1:Germany

Address

Otto-Brenner-Strasse 20, Goettingen, DEU, 37079

Website

https://www.sartorius.com

Sartorius Stedim Biotech, or SSB, is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs, and has a focus on single-use technology, or SUT. It is a subsidiary of Sartorius AG, which has a 74% ownership and 85% voting control. The business is geographically diverse.